Bristol Myers Squibb (BMY) Interest & Investment Income (2009 - 2013)
Bristol Myers Squibb (BMY) reported Interest & Investment Income of $25.0 million for Q1 2013, down 30.56% year-over-year from $36.0 million in Q1 2012, and down 30.56% quarter-over-quarter from $36.0 million in Q1 2012.
Bristol Myers Squibb (BMY) Interest & Investment Income (2009 - 2013) Analysis & Trends
Bristol Myers Squibb (BMY) has 3 years of Interest & Investment Income data on file, last reported at $25.0 million in Q1 2013.
- Interest & Investment Income for Q1 2013 came in at $25.0 million, down 30.56% year-over-year; the trailing twelve-month figure through Dec 2009 was $220.0 million (changed N/A YoY), and the FY2012 annual result was $106.0 million, up 16.48% from the prior year.
- Interest & Investment Income declined to $25.0 million in Q1 2013 per BMY's latest filing, from $36.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $220.0 million in Q4 2009 and troughed at $25.0 million in Q1 2013.
- A 3-year average of $93.7 million and a median of $36.0 million in 2012 frame the typical range for Interest & Investment Income.
- On a YoY basis, Interest & Investment Income climbed as much as 30.56% in 2013 and fell as far as 30.56% in 2013.
- A 3-year view of Interest & Investment Income shows it stood at $220.0 million in 2009, then tumbled by 83.64% to $36.0 million in 2012, then sank by 30.56% to $25.0 million in 2013.
- Business Quant data shows BMY's Interest & Investment Income at $25.0 million in Q1 2013, $36.0 million in Q1 2012, and $220.0 million in Q4 2009.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 29.66 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 229.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -645.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 25.00 Mn |
| Mar 31, 2012 | 36.00 Mn |
| Dec 31, 2009 | 220.00 Mn |